Daqing formula ameliorated allergic asthma and airway dysbacteriosis in mice challenged with ovalbumin and ampicillin

J Ethnopharmacol. 2024 Jan 10;318(Pt B):117056. doi: 10.1016/j.jep.2023.117056. Epub 2023 Aug 18.

Abstract

Ethnopharmacological relevance: Asthma is a chronic airway inflammatory disease that can lead to several complications caused by bacterial infections. However, recurrent attacks of the disease require long-term use of antibiotics, resulting in lung dysbiosis and poor outcomes. Daqing Formula (DQF) is a well-known herbal medicine in Pharmacopoeia of China, which is widely used for various stimuli-induced lower respiratory diseases, including asthma, bronchitis, and pneumonia. Thus, it has been demonstrated to be a plant-derived broad-spectrum antibiotic for treating and preventing various acute and chronic respiratory diseases.

Aim of the study: This study evaluated the efficacy and possible mechanism of DQF on allergic asthma and airway dysbiosis.

Methods and materials: The mice were co-challenged with ovalbumin and ampicillin to induce allergic asthma combined with airway dysbacteriosis. The populations of lung microbiota were detected by using 16s DNA sequencing. The levels of asthmatic markers in BALF were detected by ELISA. The levels of Th1/Th2 cytokines in splenic CD4+ cells of mice were analyzed by flow cytometry. The expressions of the GSK-3β signaling pathway in the lung tissues of asthmatic mice and eosinophils were detected by western blotting assay. The inhibition of DQF on the production of pro-inflammatory cytokines in eosinophils of asthmatic mice.

Results: The results showed that treatment with DQF at 200-800 mg/kg doses significantly reduced the frequency of nasal rubbing and lung inflammation as well as the number of total cells, eosinophils, and macrophages in bronchoalveolar lavage fluid. It decreased the relative abundances of Streptococcus, Cuoriavidus, and Moraxella, increased Akkermansia and Prevotella_6 in lung tissues of asthmatic mice, and inhibited the growth of Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae and their resistant strains in vitro. Furthermore, DQF reduced the levels of eotaxin, TSLP, IL-4, IL-5, IL-25, and IL-33, but enhanced IFN-γ and IL-12 in BALF. It elevated the population of Th1 cells, inhibited eosinophil activation, and downregulated the expressions of p-GSK-3β, p-p65, nuclear β-catenin, and p-STAT3 in the lung tissues of asthmatic mice.

Conclusions: The results revealed that DQF reduced airway inflammation, ameliorated lung dysbiosis, shifted the Th1/Th2 balance, and inhibited eosinophil activation in asthmatic mice, indicating its potential for severe asthma treatment.

Keywords: 2,4(1H, 3H)-Quinazolinedione (pubchem CID: 64048); 2-Methyl-4(3H)-Quinazolinone (pubchem CID: 135400457); 4(3H)-Quinazolinone (pubchem CID: 135408753); Antibiotic; GSK-3β; Indigo (pubchem CID: 10215); Indirubin (PubChem CID: 10177); Lung dysbiosis; Th1/Th2 balance; Tryptanthrine (pubchem CID: 73549).

MeSH terms

  • Ampicillin
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Asthma* / drug therapy
  • Dysbiosis*
  • Glycogen Synthase Kinase 3 beta
  • Mice
  • Ovalbumin

Substances

  • Ovalbumin
  • Glycogen Synthase Kinase 3 beta
  • Ampicillin
  • Anti-Bacterial Agents

Supplementary concepts

  • Pulmonary Disease, Chronic Obstructive, Severe Early-Onset